# Cambrian BioPharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cambrian-biopharma

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.cambrianbio.com
- Total disclosed funding: $125M
- Latest round: Series C (Oct 13, 2021)
- Investors on record: 9

## About

Based in New York, US, and founded in 2019 by its CEO, James Peyer, and founders Christian Angermayer and Sebastian Brunemeier, Cambrian BioPharma, Inc. is a distributed drug discovery company that collaborates with leading research institutions and start-ups, offering funding and resources to advance a portfolio of drug discovery projects with a common theme. As of 2021, Cambrian has 14 new drugs in progress across its portfolio of businesses. The company raised USD 60 million in funding in February 2021. In October 2021, Cambrian BioPharma, Inc. raised USD 100 million in series C funding co-led by Anthos Capital and Salt Ventures, with Apeiron Investment Group, Future Ventures, and Moore Capital Management.

The Cambrian BioPharma platform advances treatments and medications to reduce and treat age-related illnesses such as heart disease, cancer, and dementia, allowing scientists to transfer findings from the lab to the clinic and deliver medicines to patients in need.

Cambrian BioPharma will use the series C funding to continue advancing its existing pipeline and partner with additional scientific innovators to bring more programs under the Cambrian banner.

## Funding rounds

- Series C, Oct 13, 2021, $92M — Moore Capital Management - Private Equity, Anthos Capital, FJ Labs, Gaingels, Future Ventures, Apeiron Investment Group, Salt Ventures
- Series B, Oct 20, 2020, $28M — FJ Labs, Future Ventures, Apeiron Investment Group, Catalio Capital Management
- Series A, Oct 29, 2019, $4.8M — FJ Labs, NJF Capital

## Investors

- FJ Labs (https://capitalatlas.ai/funds/fj-labs) — Series A, Series B, Series C
- NJF Capital (https://capitalatlas.ai/funds/njf-capital) — Series A
- Future Ventures — Series B, Series C
- Apeiron Investment Group (https://capitalatlas.ai/funds/apeiron-investment-group) — Series B, Series C
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series B
- Moore Capital Management - Private Equity — Series C
- Anthos Capital (https://capitalatlas.ai/funds/anthos-capital) — Series C
- Gaingels (https://capitalatlas.ai/funds/gaingels) — Series C
- Salt Ventures — Series C